BusinessPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXSep 21, 2016, 12:05 PM UTC
